Binimetinib
From Infogalactic: the planetary knowledge core
(Redirected from MEK162)
File:Binimetinib.png | |
Systematic (IUPAC) name | |
---|---|
5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
|
|
Clinical data | |
Trade names | Binimetinib |
Legal status |
|
Identifiers | |
CAS Number | 606143-89-9 |
ATC code | none |
PubChem | CID: 10288191 |
ChemSpider | 8463660 |
ChEMBL | CHEMBL3187723 |
Chemical data | |
Formula | C17H15BrF2N4O3 |
Molecular mass | 441.23 g/mol |
|
|
|
Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma[1] to treat various cancers.
In 2015 it was in phase 3 clinical trials for ovarian cancer,[2] BRAF mutant melanoma,[3] and NRAS mutant melanoma.[4]
In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful.[5] In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment.[6]
In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.[7]
References
- ↑ "Array biopharma:: Binimetinib" [1]
- ↑ A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
- ↑ Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
- ↑ Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
- ↑ Array BioPharma Has Successful Trial for Cancer Drug Binimetinib. Dec 2015
- ↑ Array BioPharma announces Phase 3 binimetinib trial meets primary endpoint for NRAS-mutant melanoma. Dec 2015
- ↑ Array bags Phase 3 study of binimetinib in ovarian cancer; shares down 4%
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Antineoplastic and immunomodulating drug stubs
- Experimental cancer drugs
- Protein kinase inhibitors
- MEK inhibitor
- Benzamides
- Organofluorides
- Organobromides